Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268277 | 0.78 | ADORA2A (0.62) | — | |
| SCHEMBL12072478 | 0.78 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL4799051 | 0.77 | HSP90AB1 (0.46) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3272905 | 0.76 | HDAC6 (0.48) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL4797785 | 0.75 | HDAC6 (0.47) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL8647120 | 0.75 | CDK1 (0.54) | HSP90AB1HSP90AA1HSP90B1 | |
| SCHEMBL3269020 | 0.73 | ADORA2A (0.43) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3273456 | 0.73 | ADORA2A (0.50) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL28434898 | 0.71 | KDM4E (0.54) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 | |
| SCHEMBL3269601 | 0.70 | HDAC6 (0.44) | HSP90AB1HSP90AA1HDAC6HDAC1HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1349857-B1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2010-06-16 | — | — | EP | disclosed |
| US-7452894-B2 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2006-11-30 | — | — | US | disclosed |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2004-05-27 | — | — | US | disclosed |
| EP-1349857-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2003-10-08 | — | — | EP | disclosed |
| WO-2002055521-A1 | PURINE DERIVATIVES AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270691-A1 | Purine derivatives as purinergic receptor antagonists | CHRNA10, CHRNA5, CHRNA4 | HSP90AB1 3911/4885HSP90AA1 4165/4885HDAC6 3406/4885 |
| US-20040102459-A1 | Purine derivatives as purinergic receptor antagonists | OPRL1, CNR1, CNR2 | HSP90AB1 3701/4885HSP90AA1 4069/4885HDAC6 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.